lincRNA‑p21 inhibits the progression of non‑small cell lung cancer via targeting miR‑17‑5p

Ao,Xiang; Jiang,Ming; Zhou,Jie; Liang,Hongling; Xia,Haoming; Chen,Gang

doi:10.3892/or.2018.6900

lincRNA‑p21 inhibits the progression of non‑small cell lung cancer via targeting miR‑17‑5p

Authors:
- Xiang Ao
- Ming Jiang
- Jie Zhou
- Hongling Liang
- Haoming Xia
- Gang Chen
View Affiliations

Affiliations: The Second Clinical Medical College, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Thoracic Surgery Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China
Published online on: November 30, 2018 https://doi.org/10.3892/or.2018.6900
Pages: 789-800
Copyright: © Ao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small‑cell lung cancer (NSCLC) is well established as one of the major subtypes of human lung cancer. NSCLC is characterized by a high incidence rate and poor patient prognosis. Previous studies have identified that long intergenic non-coding RNA (lincRNA) serves a key role in the development of tumor and malignant metastasis. However, the majority of the underlying mechanisms for lincRNA deregulation in various diseases, including cancer and diabetes, have not been completely elucidated. In the present study, the deregulation of lincRNA‑p21 in NSCLC tumor tissues in comparison to adjacent healthy tissues was examined using reverse transcription‑quantitative polymerase chain reaction. Furthermore, the effect of lincRNA‑p21 overexpression and knockdown on different NSCLC cell lines was further investigated in vitro. The association between lincRNA‑p21 expression and microRNA (miR)‑17‑5p level in NSCLC tumor cells was also investigated to clarify the underlying mechanism. The influence of miR‑17‑5p on different NSCLC cell lines A549 and PC9 were also examined in vitro using miR‑17‑5p mimics and inhibitors. Bioinformatics and luciferase assays were conducted to verify the direct binding sites on lincRNA‑p21 for miR‑17‑5p. The results demonstrated that there was a significant low‑expression of lincRNA‑p21 in NSCLC tumor tissues, and lincRNA‑p21 effectively inhibited the progression of lung cancer cells by suppressing cell proliferation and migration and promoting cell apoptosis. An evident negative association between lincRNA‑p21 and miR‑17‑5p expression was observed, and the inhibitory effect of overexpressed lincRNA‑p21 on lung cancer cells was counteracted by miR‑17‑5p. Bioinformatics and luciferase reporter analysis results confirmed that miR‑17‑5p is a direct target for lincRNA‑p21. The present study provides evidence for lincRNA‑p21 to inhibit the progression of NSCLC via direct targeting of a miR‑17‑5p associated signaling pathway.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R: Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015. View Article : Google Scholar : PubMed/NCBI
3	D'Addario G, Früh M, Reck M, Baumann P, Klepetko W and Felip E: ESMO Guidelines Working Group: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 Suppl 5:v116–v119. 2010. View Article : Google Scholar : PubMed/NCBI
4	Giovannetti E, Toffalorio F, De PT and Peters GJ: Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: A changing landscape? Pharmacogenomics. 13:1073–1086. 2015. View Article : Google Scholar
5	Fatica A and Bozzoni I: Long non-coding RNAs: New players in cell differentiation and development. Nat Rev Genet. 15:7–21. 2014. View Article : Google Scholar : PubMed/NCBI
6	Engreitz JM, Ollikainen N and Guttman M: Long non-coding RNAs: Spatial amplifiers that control nuclear structure and gene expression. Nat Rev Mol Cell Biol. 17:756–770. 2016. View Article : Google Scholar : PubMed/NCBI
7	Quinn JJ and Chang HY: Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 17:47–62. 2016. View Article : Google Scholar : PubMed/NCBI
8	Qi P and Du X: The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 26:155–165. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wang G, Li Z, Zhao Q, Zhu Y, Zhao C, Li X, Ma Z, Li X and Zhang Y: LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. Oncol Rep. 31:1839–1845. 2014. View Article : Google Scholar : PubMed/NCBI
10	Jia M, Jiang L, Wang YD, Huang JZ, Yu M and Xue HZ: LincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through Notch signaling-induced epithelial-mesenchymal transition. Hepatol Res. 46:1137–1144. 2016. View Article : Google Scholar : PubMed/NCBI
11	Ding G, Peng Z, Shang J, Kang Y, Ning H and Mao C: LincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through miR-9/E-cadherin cascade signaling pathway molecular mechanism. OncoTargets Ther. 10:3241–3247. 2017. View Article : Google Scholar
12	Castellano JJ, Navarro A, Viñolas N, Marrades RM, Moises J, Cordeiro A, Saco A, Muñoz C, Fuster D, Molins L, et al: LincRNA-p21 impacts prognosis in resected non-small cell lung cancer patients through angiogenesis regulation. J Thorac Oncol. 11:2173–2182. 2016. View Article : Google Scholar : PubMed/NCBI
13	Wang C, Li Y, Li YW, Zhang HB, Gong H, Yuan Y, Li WT, Liu HY and Chen J: HOTAIR lncRNA SNPs rs920778 and rs1899663 are associated with smoking, male gender, and squamous cell carcinoma in a Chinese lung cancer population. Acta Pharmacol Sin. Aug 28–2018.(Epub ahead of print): View Article : Google Scholar
14	Fang L, Wu S, Zhu X, Cai J, Wu J, He Z, Liu L, Zeng M, Song E, Li J, et al: MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-β pathway in NSCLC. Oncogene. Sep 4–2018.^{(Epub ahead of print)} View Article : Google Scholar
15	Matsukuma S, Kono T, Takeo H, Hamakawa Y and Sato K: Tumor-to-tumor metastasis from lung cancer: A clinicopathological postmortem study. Virchows Arch. 463:525–534. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wei L, Wu T, He P, Zhang JL and Wu W: LncRNA ATB promotes the proliferation and metastasis of lung cancer via activation of the p38 signaling pathway. Oncol Lett. 16:3907–3912. 2018.PubMed/NCBI
17	Qi L, Liu F, Zhang F, Zhang S, Lv L, Bi Y and Yu Y: lncRNA NEAT1 competes against let-7a to contribute to non-small cell lung cancer proliferation and metastasis. Biomed Pharmacother. 103:1507–1515. 2018. View Article : Google Scholar : PubMed/NCBI
18	Liao Y, Cheng S, Xiang J and Luo C: lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients. Eur Rev Med Pharmacol Sci. 22:1686–1692. 2018.PubMed/NCBI
19	Zhou WQ, Wang P, Shao QP and Wang J: Lipopolysaccharide promotes pulmonary fibrosis in acute respiratory distress syndrome (ARDS) via lincRNA-p21 induced inhibition of Thy-1 expression. Mol Cell Biochem. 419:19–28. 2016. View Article : Google Scholar : PubMed/NCBI
20	Tu X, Zhang Y, Zheng X, Deng J, Li H, Kang Z, Cao Z, Huang Z, Ding Z, Dong L, et al: TGF-β-induced hepatocyte lincRNA-p21 contributes to liver fibrosis in mice. Sci Rep. 7:29572017. View Article : Google Scholar : PubMed/NCBI
21	Zheng J, Dong P, Mao Y, Chen S, Wu X, Li G, Lu Z and Yu F: lincRNA-p21 inhibits hepatic stellate cell activation and liver fibrogenesis via p21. FEBS J. 282:4810–4821. 2015. View Article : Google Scholar : PubMed/NCBI
22	Yang F, Zhang H, Mei Y and Wu M: Reciprocal regulation of HIF-1α and lincRNA-p21 modulates the Warburg effect. Mol Cell. 53:88–100. 2014. View Article : Google Scholar : PubMed/NCBI
23	Wu G, Cai J, Han Y, Chen J, Huang ZP, Chen C, Cai Y, Huang H, Yang Y, Liu Y, et al: lincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis and atherosclerosis by enhancing p53 activity. Circulation. 130:1452–1465. 2014. View Article : Google Scholar : PubMed/NCBI
24	Hall J, Messenger ZJ, Tam HW, Phillips SL, Recio L and Smart RC: Long non-coding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes. Cell Death Dis. 6:e17002016. View Article : Google Scholar
25	Bao X, Wu H, Zhu X, Guo X, Hutchins AP, Luo Z, Song H, Chen Y, Lai K, Yin M, et al: The p53-induced lincRNA-p21 derails somatic cell reprogramming by sustaining H3K9me3 and CpG methylation at pluripotency gene promoters. Cell Res. 25:80–92. 2015. View Article : Google Scholar : PubMed/NCBI
26	Wang J, Lei ZJ, Guo Y, Wang T, Qin ZY, Xiao HL, Fan LL, Chen DF, Bian XW, Liu J and Wang B: miRNA-regulated delivery of lincRNA-p21 suppresses β-catenin signaling and tumorigenicity of colorectal cancer stem cells. Oncotarget. 6:37852–37870. 2015.PubMed/NCBI
27	Yu F, Guo Y, Chen B, Shi L, Dong P, Zhou M and Zheng J: LincRNA-p21 inhibits the Wnt/β-catenin pathway in activated hepatic stellate cells via sponging MicroRNA-17-5p. Cell Physiol Biochem. 41:1970–1980. 2017. View Article : Google Scholar : PubMed/NCBI
28	Zhang G, An X and Zhao H, Zhang Q and Zhao H: Long non-coding RNA HNF1A-AS1 promotes cell proliferation and invasion via regulating miR-17-5p in non-small cell lung cancer. Biomed Pharmacother. 98:594–599. 2018. View Article : Google Scholar : PubMed/NCBI
29	Chatterjee A, Chattopadhyay D and Chakrabarti G: miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS One. 9:e957162014. View Article : Google Scholar : PubMed/NCBI
30	Zhang W, Lin J, Wang P and Sun J: miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells. J Drug Target. 25:125–131. 2017. View Article : Google Scholar : PubMed/NCBI